Research Alliances

• Collaboration Agreement 2009
  

• Research Collaboration 2009
• Develop Antibodies to Cancer Targets
  

• Research Agreement 2008
• Support Research to Validate Targets Expressed in Hypoxic Regions of Tumors and Therapeutic Antibodies Directed to Hypoxia Targets
  

• Exclusive License Agreement 2008
• Morphotek to Develop a Lead Human Antibody to a Cancer Antigen Developed by HMI
  

• Research Collaboration, 2008
• Morphotek to Develop Human Antibodies to Infectious Disease Pathogens and NIAID Researchers will Validate Therapeutic Activity
  

Pivotal BioSciences

• Collaboration Agreement, 2008
  

John Wayne Cancer Institute

• Research Collaboration, 2005
• Morphotek & JWCI to develop antibodies to treat melanoma and lung cancer
  

Johns Hopkins University

• Exclusive Technology License Agreement, 2000
• Cornerstone patent that helped launch the company

Ludwig Institute for Cancer Research

• Exclusive License Agreements, 2002 and 2004
• Morphotek obtained exclusive rights to MORAb-003 and MORAb-004; two therapeutic monoclonal antibodies targeting antigens
  over-expressed in various cancers.
• Research Collaboration, 2008
• Ludwig Will Use Proprietary Systems to Validate Tumor Targets
  

National Cancer Institute

• Cooperative Research and Development Agreement, 2004
• Exclusive License Agreement, 2005
• Morphotek obtained exclusive rights to MORAb-009; a monoclonal antibody targeting a glycoprotein over-expressed in pancreatic and ovarian cancers and mesotheliomas.
• Research Collaboration, 2008
• Develop and Validate Two Antibodies to Two Independent Prostate Cancer Targets
  

United States Army Medical Research Institute of Infectious Diseases "USAMRIID"

• Cooperative Research and Development Agreement, 2004
• Morphotek to develop biomolecules that kill pathogenic microbes and fully human monoclonal antibodies that protect against the toxic effects of pathogenic antigens being developed for biowarfare

United States Department of Defense

• Cooperative Research and Development Agreement, 2005
• Morphotek to develop fully human, high-affinity, antibodies that can serve as biosensors for the early detection of pathogenic agents as well as be developed as drugs for the treatment of indivisuals at risk for exposure to biowarefare agents.

Wistar Institute

• Research Collaboration Agreement, 2002
• Morphotek applied its proprietary MORPHODOMA® technology to create optimized hybridoma cell lines for Wistar